Procept BioRobotics Q4 Revenue Hits $76.4M, U.S. Procedures Jump 69%
Procept BioRobotics posted fourth-quarter revenue of $76.4 million, up 12% year-over-year, driven by 69% growth in U.S. procedures to 12,200 and a 5% sequential rise in handpiece ASP to $3,340. The company closed 2025 with 718 U.S. systems installed (42% growth) and forecasts 2026 revenue of $390 million to $410 million, a 27%-33% increase.
1. Fourth-Quarter 2025 Results
In Q4 2025 Procept BioRobotics generated $76.4 million in revenue, a 12% increase year-over-year, powered by approximately 12,200 U.S. procedures (up 69%) and 9,400 handpieces sold. Handpiece ASP rose 5% sequentially to $3,340 and the U.S. install base expanded to 718 systems, up 42%.
2. Commercial Restructuring and Pricing
The company realigned its commercial organization, launched a dedicated activation team and implemented a disciplined handpiece pricing strategy, eliminating end-of-quarter incentives and cutting field inventory. These actions caused a Q4 revenue shortfall but delivered a stronger ASP and improved long-term procedure consistency.
3. Full-Year 2025 Performance
Procept closed 2025 with $308.1 million in revenue, up 37%, and a 64% gross margin, benefiting from favorable U.S. handpiece mix. Net loss for the year was $95.6 million, while cash and equivalents totaled $289.5 million as of December 31, 2025.
4. 2026 Revenue Guidance
The company forecasts full-year 2026 revenue of $390 million to $410 million, reflecting 27%-33% growth driven by projected U.S. procedure gains of 39%-48% and a higher handpiece price of $3,500 per unit.